SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms

被引：5

作者：

Zhang, Yali ^{[1
,2
]}

He, Yufeng ^{[1
,2
]}

Liu, Siqi ^{[1
,2
]}

Deng, Li ^{[3
]}

Zuo, Yumei ^{[1
,2
]}

Huang, Keming ^{[1
,2
]}

Liao, Bin ^{[4
]}

Li, Guang ^{[1
,2
]}

Feng, Jian ^{[1
,2
]}

机构：

[1] Southwest Med Univ, Affiliated Hosp, Dept Cardiol, Key Lab Med Electrophysiol,Minist Educ, Luzhou, Peoples R China

[2] Southwest Med Univ, Inst Cardiovasc Res, Med Electrophysiol Key Lab Sichuan Prov, Luzhou, Peoples R China

[3] Southwest Med Univ, Affiliated Hosp, Dept Rheumatol, Luzhou, Sichuan, Peoples R China

[4] Southwest Med Univ, Affiliated Hosp, Dept Cardiac Surg, Luzhou, Peoples R China

来源：

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 2023年 / 23卷 / 06期

关键词：

VASCULAR ENDOTHELIAL DYSFUNCTION; NF-KAPPA-B; COTRANSPORTER; INHIBITOR; OXIDATIVE STRESS; NITRIC-OXIDE; MITOCHONDRIAL-DNA; BLOOD-PRESSURE; HEART-FAILURE; INSULIN-RESISTANCE; MACROPHAGE POLARIZATION;

D O I：

10.1007/s40256-023-00602-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Population aging combined with higher susceptibility to cardiovascular diseases in older adults is increasing the incidence of conditions such as atherosclerosis, myocardial infarction, heart failure, myocardial hypertrophy, myocardial fibrosis, arrhythmia, and hypertension. sodium-glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as a novel oral drug for patients with type 2 diabetes mellitus. Unexpectedly, recent studies have shown that, beyond their effect on hyperglycemia, SGLT2i also have a variety of beneficial effects on cardiovascular disease. Experimental models of cardiovascular disease have shown that SGLT2i ameliorate the process of aging-related cardiovascular disease by inhibiting inflammation, reducing oxidative stress, and reversing endothelial dysfunction. In this review, we discuss the role of SGLT2i in aging-related cardiovascular disease and propose the use of SGLT2i to prevent and treat these conditions in older adults.

引用

页码：641 / 662

页数：22

共 262 条

[91] Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence
Khemais-Benkhiat, Sonia
Belcastro, Eugenia
Idris-Khodja, Noureddine
Park, Sin-Hee
Amoura, Lamia
Abbas, Malak
Auger, Cyril
Kessler, Laurence
Mayoux, Eric
Toti, Florence
Schini-Kerth, Valerie B.
[J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (03) : 2109 - 2122
[92] SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
Kim, So Ra
Lee, Sang-Guk
Kim, Soo Hyun
Kim, Jin Hee
Choi, Eunhye
Cho, Wonhee
Rim, John Hoon
Hwang, Inhwa
Lee, Chan Joo
Lee, Minyoung
Oh, Chang-Myung
Jeon, Justin Y.
Gee, Heon Yung
Kim, Jeong-Ho
Lee, Byung-Wan
Kang, Eun Seok
Cha, Bong-Soo
Lee, Myung-Shik
Yu, Je-Wook
Cho, Jin Won
Kim, Jung-Sun
Lee, Yong-ho
[J]. NATURE COMMUNICATIONS, 2020, 11 (01)
[93] Cardiac sympathetic rejuvenation - A link between nerve function and cardiac hypertrophy
Kimura, Kensuke
Ieda, Masaki
Kanazawa, Hideaki
Yagi, Takashi
Tsunoda, Makoto
Ninomiya, Shin-ichi
Kurosawa, Hiroyuki
Yoshimi, Kenji
Mochizuki, Hideki
Yamazaki, Kazuto
Ogawa, Satoshi
Fukuda, Keiichi
[J]. CIRCULATION RESEARCH, 2007, 100 (12) : 1755 - 1764
[94] Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Kohan, Donald E.
Fioretto, Paola
Tang, Weihua
List, James F.
[J]. KIDNEY INTERNATIONAL, 2014, 85 (04) : 962 - 971
[95] Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus
Kohlmorgen, Christina
Gerfer, Stephen
Feldmann, Kathrin
Twarock, Soeren
Hartwig, Sonja
Lehr, Stefan
Klier, Meike
Krueger, Irena
Helten, Carolin
Keul, Petra
Kahl, Sabine
Polzin, Amin
Elvers, Margitta
Floegel, Ulrich
Kelm, Malte
Levkau, Bodo
Roden, Michael
Fischer, Jens W.
Grandoch, Maria
[J]. DIABETOLOGIA, 2021, 64 (08) : 1834 - 1849
[96] 23Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients
Kopp, Christoph
Linz, Peter
Dahlmann, Anke
Hammon, Matthias
Jantsch, Jonathan
Mueller, Dominik N.
Schmieder, Roland E.
Cavallaro, Alexander
Eckardt, Kai-Uwe
Uder, Michael
Luft, Friedrich C.
Titze, Jens
[J]. HYPERTENSION, 2013, 61 (03) : 635 - +
[97] Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
Koyani, Chintan N.
Plastira, Ioanna
Sourij, Harald
Hallstrom, Seth
Schmidt, Albrecht
Rainer, Peter P.
Bugger, Heiko
Frank, Sasa
Malle, Ernst
von Lewinski, Dirk
[J]. PHARMACOLOGICAL RESEARCH, 2020, 158
[98] Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes
Kraakman, Michael J.
Lee, Man K. S.
Al-Sharea, Annas
Dragoljevic, Dragana
Barrett, Tessa J.
Montenont, Emilie
Basu, Debapriya
Heywood, Sarah
Kammoun, Helene L.
Flynn, Michelle
Whillas, Alexandra
Hanssen, Nordin M. J.
Febbraio, Mark A.
Westein, Erik
Fisher, Edward A.
Chin-Dusting, Jaye
Cooper, Mark E.
Berger, Jeffrey S.
Goldberg, Ira J.
Nagareddy, Prabhakara R.
Murphy, Andrew J.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (06) : 2133 - 2147
[99] Influence of Acquired and Genetic Risk Factors on the Prevention, Management, and Treatment of Thromboembolic Disease
Kreidy, Raghid
[J]. INTERNATIONAL JOURNAL OF VASCULAR MEDICINE, 2014, 2014
[100] Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Kristensen, Soren L.
Rorth, Rasmus
Jhund, Pardeep S.
Docherty, Kieran F.
Sattar, Naveed
Preiss, David
Kober, Lars
Petrie, Mark C.
McMurray, John J. V.
[J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (10) : 776 - 785

← 5 6 7 8 9 10 11 12 13 14 →